Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXSWF6)

Drug Name

grayanotoxin III Drug Info

Synonyms

grayanotoxin III; UNII-ZKR09NT58C; Andromedol; ZKR09NT58C; Deacylasebotoxin I; Deacetylandromedotoxin; 4678-45-9; NSC 323778; BRN 2059374; Grayanotoxane-3,5,6,10,14,16-hexol, (3-beta,6-beta,14R)-; grayanotoxin-III; (3beta,6beta,14R)-Grayanotoxane-3,5,6,10,14,16-hexol; GTPL2628; CHEMBL454313; SCHEMBL1008212; 7,9a-Methano-9aH-cyclopenta(b)heptalene-2,4,8,11,11a,12(1H)-hexol, dodecahydro-1,1,4,8-tetramethyl-, (2S,3as,4R,4ar,7R,8R,9as,11R,11aR,12R)-; ZINC33913426; Grayanotoxane-3,5,6,10,14,16-hexol, (3beta,6beta,14R)- (9CI)

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 11057730
CAS Number: CAS 4678-45-9
TTD Drug ID: DMXSWF6

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.4 (SCN4A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lanperisone	DM4EGPN	Musculoskeletal disorder	FA00-FC0Z	Phase 3	[3]
SIPATRIGINE	DMMQ4GC	Neurological disorder	6B60	Discontinued in Phase 2	[4]
V-102862	DMR2EUV	N. A.	N. A.	Discontinued in Phase 1	[5]
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[6]
veratridine	DMUF8JZ	Discovery agent	N.A.	Investigative	[6]
BW-202W92	DMFKXMT	Discovery agent	N.A.	Investigative	[4]
CCNCSSKWCRDHSRCC	DMBGHTW	Discovery agent	N.A.	Investigative	[7]
CCNCSSKWCRAHSRCC	DM96YR2	Discovery agent	N.A.	Investigative	[7]
CCACSSKWCRDHSRCC	DMSE20Y	Discovery agent	N.A.	Investigative	[7]
CCNCASKWCRDHSRCC	DMRFA5O	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.4 (SCN4A)	TT84DRB	SCN4A_HUMAN	Activator	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2628).
2	Novel site on sodium channel alpha-subunit responsible for the differential sensitivity of grayanotoxin in skeletal and cardiac muscle. Mol Pharmacol. 2001 Oct;60(4):865-72.
3	Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
4	Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707.
5	3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. J Med Chem. 2004 Mar 11;47(6):1547-52.
6	Point mutations in segment I-S6 render voltage-gated Na+ channels resistant to batrachotoxin. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2653-8.
7	Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706.